STORZ MEDICAL’s MAGNETOLITH receives CE approval

A career in sport does not eliminate risk of cardiovascular disease; A systematic review and meta-analysis of the cardiovascular health of field-based athletes
22 février 2020
Examining the evolution and classification of player position using performance indicators in the National Rugby League during the 2015-2019 seasons
28 février 2020

STORZ MEDICAL’s MAGNETOLITH receives CE approval

In February 2020, STORZ MEDICAL has received the CE approval for the MAGNETOLITH® system, which is the successor of the CELLACTOR® MT1. Extracorporeal Magnetotransduction Therapy (EMTT®) with the MAGNETOLITH® opens up new possibilities in regeneration and rehabilitation. The areas of application include diseases of the musculoskeletal system such as lower back pain and tendinopathies of the rotator cuff or Achilles tendon. The non-invasive, outpatient therapy is virtually free of side effects.

Powered by WPeMatico

Comments are closed.